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Stage I NSCLC can be cured with radical surgery; the reported 5-years overall survivalrate ranged from 55% up more than 70%.1 Even with modern techniques there is a low,
but nonzero, in-hospital death rate of 0.8%.2 Lobectomy, performed by thoracothomy or
video-assisted thoracoscopic approach is the surgical procedure of choice, being more
limited resection less effective in local control rates. Loss of pulmonary parenchyma has
a negative impact on respiratory function and can reflect in a decreased quality of life. In
the past, patients unable to withstand lobectomy and/or the related surgical stress have
been traditionally treated with standard radiotherapy (RT) at doses of about 60 Gray. The
outcomes were clearly inferior to those of surgery with reported 5-years overall survival
of 23%.3 Modern high precision photons radiotherapy (Image-Guided RT and others) can
be substantially more effective.4 For example, stereotactic technique (SRT) allow to
selectively deliver higher doses to the detectable tumor (plus a margin). Hypofractionated
schedules with only few (typically less than 5) treatment sessions are given. A large
retrospective analysis has shown that, with a biological equivalent dose greater than 100
Gray, the 3-years overall survival rate was 88% and local control rivalled with the best
surgical series.5 Based on the preliminary results obtained in many phase I and phase II
trials, two new trials are about to start (RTOG 0618 and Japan Clinical Oncology Group
0403) in which SRT will not be limited to inoperable patients but will be proposed as an
alternative to surgery.6
Protontherapy (PT) has been used for small series of inoperable stage I NSCLC with
promising results. Carbon ion radiotherapy (CIRT) has been used only in two Japanese
centers (Hyogo Ion Beam Medical Centre, HIBMC and Heavy Ion Medical Accelerator
in Chiba, HIMAC) and only HIMAC has published its early results.7 In this limited
scenario the role of hadrontherapy is not still clearly defined, with major concerns in terms
of cost-effectiveness and results based on evidence.8,9
Thanks to their favorable physical characteristics both carbon ions and protons are
able to deliver high doses to target volumes of complex shapes at least as well as other
high precision RT techniques. They are furthermore capable to significantly reduce the
volume of lung parenchyma receiving middle and low doses, and to reduce almost to zero
irradiation of other organs (heart, esophagus, and spinal cord). CIRT has the theoretical
advantage over PT of delivering a radiation with an increased radiobiological efficacy
(RBE) and thus possibly killing also radioresistant clonogenes. The high RBE is selec-
tively limited to the target with normal tissues receiving a low RBE radiation; therefore
the possible increase in local control can be achieved without any increase in the risk of
toxicity. The only theoretical disadvantage of PT and CIRT is their increased risk of
geographic miss. Not only organ motion but also organ deformation can significantly
affect the actual delivered dose and must be specifically addressed.
In their current article Miyamoto et al10 report the excellent results achieved with a
four fractions schedule of CIRT for stage I NSCLC patients that were either inoperable or
refused surgery. In this and in their previous papers the treatment techniques was
described, giving details on the gating procedures used to deal with organ motion and
on the special strategies necessary to expand the GTV accounting for the finite range of
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penetration of carbon ions. The group from HIMAC has
moreover reported data on late pulmonary toxicity after
CIRT, assessed both radiologically and with functional spi-
rometric tests. Results of CIRT for lung cancer are to be
considered extremely interesting and this treatment modality
appears safe and effective. Until now the main limit of PT
and CIRT seems to be their scarce availability.
Unfortunately to day it is definitely not possible to
compare results obtained with CIRT and with other RT
techniques. Different dose and different schedules employed,
different follow up available, different strategies for organ
motion control would make such a comparison extremely
difficult. Anyway the key factor that makes such a compar-
ison impracticable is the difference in selection criteria used.
For example patients treated with SRT in Japan tend to show
a better outcome, at the same dose levels, compared with
those treated in Europe and USA.5 This has been attributed to
a selection bias possibly deriving from a less aggressive
approach of Japanese surgeons.
A prospective randomized trial is the only tool that will
be able to tell if the potential advantages of PT over SRT and
of CIRT over PT are of clinical relevance.8 The endpoints of
this trial should include local control and late toxicity. Pre-
serving respiratory function is of paramount importance and
PT and CIRT may be beneficial, on the other hand the
reported costal bone fractures after CIRT may be a concern.
Such a trial would require the coordinated efforts of radiation
oncologists from traditional and hadrontherapy centers. As
soon as data from PT and CIRT will be more mature these
treatments could be included in trials comparing surgery and
radiotherapy.
One of the most common arguments against hadron-
therapy is its greater economic costs.9 CIRT is more expen-
sive than PT which is in turn more expensive than SRT or
other RT tecniques; but any RT technique is much less
expensive than the golden standard of lobectomy. Cost and
cost-effectiveness are therefore of minor concern for NSCLC
and we believe that the only ethical approach would be to
strive for the most effective kind of radiotherapy as it will
anyway result in a saving compared to surgery.
Finally, it is worth mentioning that patients surviving a
first lung cancer have an increased risk of developing a
second NSCLC of about 10%. PT and CIRT could offer the
advantage of an easier second radical radiotherapy even
though it would be very difficult to measure it in a trial.
In conclusion, CIRT is a promising treatment that needs
to be tested against other advanced techniques with a meth-
odologically sound approach. After the pioneering works of
HIMAC many new carbon ion facilities are nowadays being
built and will hopefully allow carrying out the indispensable
phase III trials.
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